Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Accumulated Expenses (2016 - 2020)

Historic Accumulated Expenses for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to $3.4 million.

  • Larimar Therapeutics' Accumulated Expenses fell 649.35% to $3.4 million in Q3 2020 from the same period last year, while for Sep 2020 it was $3.4 million, marking a year-over-year decrease of 649.35%. This contributed to the annual value of $2.3 million for FY2019, which is 4698.43% down from last year.
  • As of Q3 2020, Larimar Therapeutics' Accumulated Expenses stood at $3.4 million, which was down 649.35% from $3.8 million recorded in Q2 2020.
  • Larimar Therapeutics' Accumulated Expenses' 5-year high stood at $6.7 million during Q1 2016, with a 5-year trough of $981000.0 in Q1 2020.
  • Moreover, its 5-year median value for Accumulated Expenses was $3.7 million (2016), whereas its average is $3.8 million.
  • In the last 5 years, Larimar Therapeutics' Accumulated Expenses surged by 6705.5% in 2016 and then plummeted by 7026.37% in 2020.
  • Over the past 5 years, Larimar Therapeutics' Accumulated Expenses (Quarter) stood at $3.7 million in 2016, then grew by 14.47% to $4.3 million in 2017, then decreased by 0.28% to $4.3 million in 2018, then crashed by 46.98% to $2.3 million in 2019, then surged by 49.8% to $3.4 million in 2020.
  • Its last three reported values are $3.4 million in Q3 2020, $3.8 million for Q2 2020, and $981000.0 during Q1 2020.